biotech / news / / The Tribune
The project is being implemented under an Indo-Singapore collaborative framework in partnership with Biocell Innovations.
The Technology Development Board partnered with Helix Cell Therapeutics to develop dual-targeting CAR-T therapy for Multiple Myeloma.
KEY POINTS
- The new CAR-T therapy will simultaneously target BCMA and CD19 markers on Multiple Myeloma cells.
- This project operates under an Indo-Singapore collaborative framework with Biocell Innovations as a partner.
- The initiative includes conducting a Phase I clinical trial for patients who have exhausted current treatment options.
- This project aims to accelerate indigenous innovation in advanced immunotherapy and strengthen India's biotech capabilities.
COMPANIES
Summarized by Newsio from The Tribune. How we summarize →